SharePitch
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed

Avivagen Reports Positive Proof of Concept in Preventing C. Difficile Infection

4/10/2017

0 Comments

 
Picture
Avivagen Inc. (TSX-V: VIV) (OTC Pink: CHEXF) announced positive results from a proof-of-concept study that could extend Avivagen’s OxC-beta™ technology into human health applications.

The proof-of-concept study evaluated Avivagen’s OxC-beta™ technology as a preventative therapeutic against C. difficile infection (CDI). As strains of C. difficile change, antibiotics are becoming less effective or even completely ineffective in clearing CDI.  It is estimated that CDI adds an annual economic burden of US$1.5 billion to the United States healthcare system.

Picture
Dr. James Nickerson
“We are very pleased with the outcome of this study, which establish proof of concept for the application of our OxC-beta™ technology in preventing C. difficile infection. We are now planning to move forward, in collaboration with the NRC, to conduct additional pre-clinical studies that will test higher doses of our technology to determine its effective dose range — with the ultimate goal of evaluating the technology in humans.” - Dr. James Nickerson, Avivagen’s Director of Product Validation
 
The proof-of-concept study evaluated three doses of the OxC-beta™ technology for the ability to improve survival rate, increase median time until death, and improve clinical indicators of health using a standard mouse model of human C. difficile infection. The research was conducted by the National Research Council of Canada (NRC), the Government of Canada’s premier research organization supporting industrial innovation, the advancement of knowledge, technology development, and fulfilling government mandates.

The results of the study demonstrate that the highest dose of the OxC-beta™ technology tested increased survivability and clinical scores in mice compared to the un-supplemented mouse control group. Treatment with the OxC-beta™ technology increased median time until death to greater than seven days in the mouse group treated with OxC-beta compared to only three days in the un-supplemented mouse control group.

About Avivagen

Avivagen Inc. is a public company traded on the TSX-V under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.


About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.


Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
0 Comments



Leave a Reply.

    Archives

    November 2020
    October 2020
    July 2020
    June 2020
    March 2020
    February 2020
    November 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017

    Categories

    All
    Avivagen
    DiaMedica
    Fertility
    Heisler Healthcare Weekly
    Medical Device
    Private Equity
    Ventripoint Diagnostics

    RSS Feed

Terms of Use